Report Categories

The global Medical Inhaled Nitric Oxide market size is expected to reach $ 1921.1 million by 2030, rising at a market growth of 8.6% CAGR during the forecast period (2024-2030).

USD4480.00

Add To Cart

According to our (Global Info Research) latest study, the global Medical Inhaled Nitric Oxide market size was valued at USD 1077.4 million in 2023 and is forecast to a readjusted size of USD 1921.1 million by 2030 with a CAGR of 8.6% during review period.

USD3480.00

Add To Cart

Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator). Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone. The therapeutic application of iNO in human was first described in 1990s. INO therapy was effective to improve oxygenation in infants with persistent pulmonary hypertension of the newborn (PPHN). Owing to its selective pulmonary vasodilator effects, iNO therapy is an important treatment for term newborns with hypoxemic respiratory failure due to PPHN. The Food and Drug Administration of the United States of America first approved iNO in 1999 for use as a medical gas to treat hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Thereafter, iNO therapy is clinically applied to treat PPHN in term and late preterm neonates without consensus.

USD3480.00

Add To Cart